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Abstract
Background: The tcdA-negative variant (A-B+) of Clostridium difficile is prevalent in East Asian countries. However,
the risk factors and clinical characteristics of A-B+ C. difficile infections (CDI) are not clearly documented. The
objective of this study was to investigate these characteristics.
Methods: From September 2008 through January 2010, the clinical characteristics, medication history and
treatment outcomes of CDI patients were recorded prospectively. Toxin characterization and antibiotic susceptibility
tests were performed on stool isolates of C. difficile.
Results: During the study period, we identified 22 cases of CDI caused by tcdA-negative tcdB-positive (A-B+) strains
and 105 cases caused by tcdA-positive tcdB-positive (A+B+) strains. There was no significant difference in disease
severity or clinical characteristics between the two groups. Previous use of clindamycin and young age were
identified as significant risk factors for the acquisition of A-B+ CDI (OR = 4.738, 95% CI 1.48–15.157, p= 0.009 and
OR= 0.966, 95% CI 0.935–0.998, p= 0.038, respectively) in logistic regression.
Rates of resistance to clindamycin were 100% and 69.6% in the A-B+ and A+B+ isolates, respectively (p= 0.006), and
the ermB gene was identified in 17 of 21 A-B+ isolates (81%). Resistance to moxifloxacin was also more frequent in
the A-B+ than in the A+B+ isolates (95.2% vs. 63.7%, p= 0.004).
Conclusions: The clinical course of A-B+ CDI is not different from that of A+B+ CDI. Clindamycin use is a significant
risk factor for the acquisition of tcdA-negative variant strains.
Keywords: Clostridium difficile infection, tcdA-negative variant strain, Clinical outcome, Risk factor, Antimicrobial
susceptibility test, ermB gene
Background
Clostridium difficile infection (CDI) is a major cause of
healthcare-associated infections worldwide. While the
hypervirulent ribotype 027 strain with binary toxin has
led to outbreaks only in North America and Europe
[1,2], toxin A-negative (A-B+) C. difficile infections have
been reported worldwide [3-5]. The A-B+ strain infec-
tions occur in an epidemic or sporadic form worldwide,
while A-B+ CDI is more frequent in East Asian countries
[4,6-9].
Initially toxin A was considered to be the most import-
ant factor responsible for diarrheal disease [5]; however,
several reports have documented that A-B+ strains can
lead to similar symptoms, from mild diarrhea to severe
pseudomembranous colitis [10,11]. The risk factors and
clinical characteristics of A-B+ CDI have not been clearly
documented.
In this study, we investigated the presence of A-B+ strains in
healthcare-associated CDI (HA-CDI) in Korea, compared the
clinical characteristics of A-B+ CDI and A+B+ (tcdA-positive
tcdB-positive) CDI, and analyzed the risk factors for acquisition
of A-B+ CDI. We also assessed the susceptibilities to clindamy-
cin and moxifloxacin of the A-B+ and A+B+ strains.
Methods
Setting and study design
This study was conducted at Hanyang University Hos-
pital, a 900-bed tertiary care facility located in Seoul,
South Korea. From September 2008 through January
2010, we enrolled suspected HA-CDI patients and recorded
prospectively their clinical characteristics. After isolation of
C. difficile from patients’ stools, microbiologic studies were
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performed. To compare the effects of 'toxin A and toxin B'
strains and 'toxin B alone' strains on clinical characteristics,
patients infected with A+B+ and A-B+ strains were enrolled,
while those with binary toxin-positive isolates were
excluded. This study was approved by the institutional re-
view board of Hanyang University Hospital (HYUH IRB
2010-R-12).
Definitions
Diarrhea was defined as unformed stools more than 3
times per day on consecutive days, or 6 times within 36 h.
CDI was diagnosed when patients had diarrhea and the
C. difficile stool isolates contained toxin genes detected by
multiplex PCR [12]. We diagnosed HA-CDI when CDI
developed at least 72 h after hospitalization, or within 2
months of the last discharge if the patient did spend time
in a healthcare facility [13].
Clinical cure was defined as resolution of diarrhea
within the treatment period, and clinical failure as the
need for treatment change to resolve the diarrhea. Reso-
lution of diarrhea required conversion to two or fewer
semi-formed or formed stools per day [14]. Recurrence
was defined as growth of toxinogenic C. difficile, a posi-
tive A&B toxin assay (VIDAS® C. difficile Toxins A & B;
BioMerieux SA, Marcy l’Etoile, France), or a pseudo-
membrane on endoscopy, with resurgence of symptoms
after cessation of treatment at least 10 days after the first
episode [15]. Global cure was defined as clinical cure
without recurrence.
Collection of data
The demographic and clinical data collected in the study
were age, sex, length of hospital stay, medication history
within the past 2 months, and underlying diseases in-
cluding Charlson scores. Installation of a catheter, the
use and dosage of antibiotics, probiotics, proton pump
inhibitors, H2 blockers, steroids, chemotherapy, and surgi-
cal procedure within the past 2 months, were investigated
as potential risk factors for CDI [16]. Past medication his-
tory was obtained from medical records. The amount of
antibiotics administered was expressed as the number of
defined daily doses (DDD), which means the total amount
of antibiotic divided by the DDD [17].
Vital signs, stool character, stool frequency, and ab-
dominal pain and tenderness were monitored within 24 h
after inclusion. Laboratory tests such as white blood cell
(WBC) count, albumin and C-reactive protein (CRP) levels
were performed within 24 h of enrollment. Age >60 years,
temperature >38.3°C, albumin level <2.5 mg/dL, and
WBC count >15,000 cells/mm3 received 1 point each, and
the scores were summed for each patient. Scores above 2
were defined as severe CDI [18,19].
Microbiologic studies
Stool specimens were grown anaerobically on C. difficile-
selective cycloserine-cefoxitin-taurocholate agar (CCFA-
TA, Oxoid Ltd., Cambridge, UK), supplemented with 7%
horse blood, after alcohol shock treatment [20]. Colonies
of C. difficile were identified with API® Rapid ID 32A
(BioMerieux SA, Marcy l’Etoile, France). ATCC 43598
and PCR-ribotype 027 (BI/NAP1/027) were used as in-
ternal controls.
Template DNA from stool isolates was used in multi-
plex PCR to investigate the presence of toxin genes, as
described elsewhere, with minor modifications [12].
After the strains producing binary toxin were excluded
by multiplex PCR, toxin typing was performed [21].
Minimum inhibitory concentrations (MICs) of clinda-
mycin and moxifloxacin were measured on supplemented
Brucella agar by the E-test (AB-BIOdisc, Solna, Sweden),
as recommended by the Clinical and Laboratory Standards
Institute (CLSI) [22]. C. difficile ATCC 700057 was used as
quality control strain for susceptibility testing.
PCR was performed on template DNA to detect the
ermB gene [23]. A PCR product of 688 base pairs on
electrophoresis was considered a positive result.
Statistical methods
SPSS version 18.0 for Windows (SPSS Inc., Chicago, IL,
USA) was used for statistical analysis. Categorical vari-
ables were analysed using Pearson’s chi-square test or
Fisher’s exact test. Continuous variables were analysed
using an independent t-test or the Mann–Whitney U-
test. Variables with p-values <0.1 on univariate analysis
were included in the multivariate analysis. A p-value
<0.05 in a two-tailed test of significance was considered
statistically significant.
Results
During the study period, 138 C. difficile isolates were
obtained from HA-CDI patients; 11 isolates (8.0%) were
confirmed by multiplex PCR to have binary toxin genes,
22 (15.9%) were A-B+ strains, and 105 (76.1%) were A+B+
strains. Consequently, 22 patients with A-B+ strains and
105 with A+B+ strains were enrolled.
Comparison of the demographic and clinical
characteristics of the A-B+ and A+B+ CDI groups
Demographic and clinical characteristics were compared
in the 22 A-B+ patients and the 105 A+B+ patients
(Table 1). There were no differences in age, sex, length
of hospital stay, history of recent surgery or Charlson
score between the two groups; however, more cases of
chronic obstructive pulmonary disease (COPD) as an
underlying disease were identified in the A-B+ group
(p= 0.049). No differences were found between the two
groups with regard to factors associated with the CDI
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severity score. Using a definition of severe CDI adapted
from Zar et al. [18,19], severe CDI occurred at a similar
rate in the A+B+ and the A-B+ group (19% and 18.2% re-
spectively, p= 0.925). WBC counts and CRP levels were
higher and the albumin level lower in the A+B+ CDI
group, but these differences was not statistically signifi-
cant. Clinical characteristics associated with CDI, such as
stool frequency, mucoid stool, abdominal pain or tender-
ness, were not significantly different between the groups.
The A-B+ group was 1.067 times more likely to develop
pseudomembranous colitis than the A+B+ group, as mea-
sured by odds ratio.
Comparison of outcomes in the A-B+ and A+B+ CDI groups
Of the 127 patients with HA-CDI, 7 were discharged be-
fore diagnosis and 3 died from an underlying disease
before they had begun treatment. In 32 patients, diarrhea
improved or resolved without treatment, and 85 patients
(16 A-B+ and 69 A+B+ CDI cases) completed treatment
(16/22 vs. 69/105, p= 0.623). Treatment outcomes were
compared in the two groups. The treatment regimens
(metronidazole or vancomycin) did not differ signifi-
cantly (p= 0.681). The rates of global cure, failure and
mortality were respectively 62.3%, 5.8% and 10.1% in the
A+B+ group and 75%, 12.5% and 12.5% in the A-B+ group
(p= 0.398, 0.315, and 0.675, respectively) (Table 2). One
case of mortality attributable to CDI occurred in the A+
B+ group. Additionally 15 of 69 patients (21.7%) in the
A+B+ group and none in the A-B+ group (0/16) experi-
enced CDI recurrence after completion of treatment;
however, the difference in recurrence rate between the
groups did not reach statistical significance (p= 0.063).
Table 1 Demographic and clinical characteristics of patients infected with Clostridium difficile tcdA-positive tcdB-
positive (A+B+) strains and with tcdA-negative tcdB-positive (A-B+) strains
A+B+ (n = 105) A-B+ (n = 22) p value a
Sex (female) N (%) 54 (51.4) 8 (36.4) 0.244
Age Mean (SD) 65.2 (15.10) 58.5 (19.12) 0.143
Length of hospital stay Mean (SD) 34.8 (44.41) 24.3 (21.20) 0.583
Charlson score Mean (SD) 3.17 (2.482) 2.50 (2.345) 0.172
Underlying disease
COPD N (%) 8 (7.6) 5 (22.7) 0.049
CVA N (%) 28 (26.7) 2 (9.1) 0.100
Surgical procedure N (%) 28 (26.7) 2 (9.1) 0.100
Severity score Mean (SD) 0.96 (0.746) 1.00 (0.873) 0.961
Old age b N (%) 67 (63.8) 12 (54.5) 0.472
Fever c N (%) 10 (9.5) 5 (22.7) 0.137
Hypoalbuminemia d N (%) 10 (9.5) 1 (4.5) 0.688
Leukocytosis e N (%) 14 (13.3) 4 (18.2) 0.515
Severe CDI f N (%) 20 (19.0) 4 (18.2) 0.925
Clinical findings
Pain N (%) 25 (23.8) 10 (45.5) 0.063
Tenderness N (%) 36 (34.3) 10 (45.5) 0.338
Stool Fr ≥10/day N (%) 21 (20.4) 2 (9.1) 0.362
Mucoid stool N (%) 19 (18.1) 8 (36.4) 0.083
Laboratory findings
WBC (cells/mm3) Mean (SD) 10892 (5527) 10263 (7746) 0.239
Albumin (mg/dL) Mean (SD) 3.1 (0.57) 3.4 (0.53) 0.073
CRP (mg/dL) Mean (SD) 7.40 (6.397) 5.98 (6.194) 0.139
Pseudomembrane g N (%) 10/26 (38.5) 2/5 (40.0)
A+B+, tcdA-positive tcdB-positive strain; A-B+, tcdA-negative tcdB-positive strain; COPD, chronic obstructive pulmonary disease; CVA, cerebrovascular accident; ICU,
intensive care unit; Fr, frequency; CDI, Clostridium difficile infection; WBC, white blood cell; CRP, C-reactive protein.
a From Fisher’s exact test for categorical variables or the Mann–Whitney U-test for continuous variables.
b Defined as age >60 years.
c Defined as temperature >38.3°C.
d Defined as albumin level <2.5 mg/dL.
e Defined as a WBC count >15,000 cells/mm.3
f Severity scores >2 points were regarded as severe CDI.
g Denominator comprises patients examined by endoscopy.
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Clinical outcomes were not significantly different be-
tween the metronidazole and vancomycin treatment
groups (measured in all patients, p for trend = 0.597).
Comparison of previous medication history in the A-B+
and A+B+ groups
Medication histories of the patients were obtained by
retrospective review of their medical records. After ex-
cluding 5 cases of HA-CDI due to incomplete medical
records, 21 cases of A-B+ CDI and 101 cases of A+B+
CDI were included in the analysis (Table 3).
Previous use of proton pump inhibitors, H2 blockers,
probiotics, steroids or chemotherapy was not signifi-
cantly different between the groups. The most commonly
prescribed antibiotics in the A+B+ CDI group were
extended-spectrum cephalosporins (ESCs) (56.4%) fol-
lowed by fluoroquinolones (45.5%) and beta-lactam/beta-
lactamase inhibitors (35.6%), while in the A-B+ group
they were fluoroquinolones (66.7%), clindamycin (52.4%)
or ESCs (52.4%). Calculating the amount of antibiotics as
Table 2 Comparison of clinical outcomes in patients
infected with tcdA-positive tcdB-positive (A+B+) strains of
Clostridium difficile and those infected with tcdA-negative
tcdB-positive (A-B+) strains
Clinical outcome Group p
valueA+B+ (n (%)) A-B+ (n (%))
Global cure 43 (62.3) 12 (75.0) 0.398
Failure 4 (5.8) 2 (12.5) 0.315
Death 7 (10.1) 2 (12.5) 0.675
Recurrence 15 (21.7) 0 (0.0) 0.063
Total 69 (100.0) 16 (100.0)
A+B+, tcdA-positive tcdB-positive strain; A-B+, tcdA-negative tcdB-positive strain.
Table 3 Previous medication in patients infected with tcdA-positive tcdB-positive (A+B+) strains of Clostridium difficile
and with tcdA-negative tcdB-positive (A-B+) strains
A+B+ (n = 101) A-B+ (n = 21) P value a
Medication
PPI N (%) 35 (34.7) 6 (28.6) 0.800
H2 blockers N (%) 49 (48.5) 8 (38.1) 0.474
Probiotics N (%) 49 (48.5) 13 (61.9) 0.339
Steroids N (%) 37 (36.6) 7 (33.3) 1.000
Chemotherapy N (%) 12 (11.9) 3 (14.3) 0.722
Antibiotics
All-DDD Mean (SD) 25.4 (18.91) 27.0 (21.83) 0.989
Days of antibiotic use Mean (SD) 18.7 (12.25) 16.6 (12.23) 0.317
Antibiotics use
Fluoroquinolones N (%) 46 (45.5) 14 (66.7) 0.096
2nd Quinolones N (%) 22 (21.8) 8 (38.1) 0.161
3rd Quinolones N (%) 34 (33.7) 9 (42.9) 0.458
Clindamycin N (%) 17 (16.8) 11 (52.4) 0.001
ESC N (%) 57 (56.4) 11 (52.4) 0.811
BL/BLI N (%) 36 (35.6) 6 (28.6) 0.620
Carbapenem N (%) 10 (9.9) 2 (9.5) 1.000
Glycopeptides N (%) 20 (19.8) 2 (9.5) 0.360
Metronidazole N (%) 29 (28.7) 3 (14.3) 0.275
Antibiotics dose
Fluoroquinolones Mean (SD) 5.606 (9.2145) 7.138 (10.0394) 0.202
2nd Quinolones Mean (SD) 1.858 (5.1504) 2.210 (4.7322) 0.168
3rd Quinolones Mean (SD) 3.737 (7.2372) 4.929 (9.3117) 0.484
Clindamycin Mean (SD) 1.111 (3.1081) 4.302 (5.1853) <0.0001
ESC Mean (SD) 5.260 (7.7728) 3.595 (4.5188) 0.611
BL/BLI Mean (SD) 3.825 (9.2440) 3.536 (8.2533) 0.611
Carbapenem Mean (SD) 0.636 (3.3368) 0.524 (1.7210) 0.995
Glycopeptides Mean (SD) 1.255 (3.4253) 0.548 (1.9359) 0.270
Metronidazole Mean (SD) 2.850 (6.9772) 1.397 (3.7901) 0.194
A+B+, tcdA-positive tcdB-positive strain; A-B+, tcdA-negative tcdB-positive strain; PPI, proton pump inhibitor; DDD, defined daily dose; ESC, extended-spectrum
cephalosporins; BL/BLI, beta-lactam/beta-lactamase inhibitor.
a From Fisher’s exact test for categorical variables or the Mann–Whitney U-test for continuous variables.
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DDD showed that, in the A+B+ group, the order of anti-
biotics by quantity was similar to the order by frequency
of use. In the A-B+ group, antibiotics consumed in largest
quantities were fluoroquinolones, clindamycin and ESCs.
Finally, a comparison of previous use and amount of
antibiotics in the two groups showed that both the use
and amount of clindamycin were significantly higher in
the A-B+ group (p=0.001 and p< 0.0001, respectively).
Risk factors for A-B+ strain acquisition
We performed a multivariate logistic regression analysis
to identify the risk factors for acquisition of tcdA-negative
strains. Age, sex, chronic obstructive pulmonary disease as
an underlying disease, albumin level, and quinolone and
clindamycin use were included in the analysis. Previous
use of clindamycin was found to be a significant risk factor
for A-B+ C. difficile infection (OR=4.738, 95% CI 1.481–
15.157, p=0.009). Age also had a statistically significant ef-
fect (OR=0.966, 95% CI 0.935–0.998, p=0.038) (Table 4).
Microbiologic studies
Toxinotyping was performed on the 138 isolates of C.
difficile; 104 of the 105 A+B+ isolates (99.0%) belonged
to toxinotype 0, and one isolate to toxinotype I; all 22
isolates of the A-B+ strain were toxinotype VIII; 8 of 11
binary toxin-producing isolates were toxinotype IV and 3
isolates, toxinotype III.
Clindamycin and moxifloxacin susceptibility testing
was performed on only 123 isolates (21 A-B+ isolates and
102 A+B+ isolates) because subculture failed in the case
of 4 isolates.
The A-B+ strains had significantly higher resistance
rates to clindamycin and moxifloxacin than the A+B+
strains (p = 0.006 and 0.004, respectively). In the A-B+
group, the resistance rates to clindamycin and moxiflox-
acin were 100% (MIC range 16 6–> 256 mg/L) and
95.2% (MIC range 2–32 mg/L), respectively, whereas in
the A+B+ group they were 69.6% and 63.7%, respectively,
with wide ranges of MIC (MIC range 1.5–> 256 mg/L
and <0.25–128 mg/L, respectively). Resistance to moxi-
floxacin was correlated with resistance to clindamycin
(P< 0.0001). The moxifloxacin resistance rate among
clindamycin-resistant A+B+ isolates was 88.7% (63/71)
compared with 6.5% (2/31) among clindamycin-suscep-
tible A+B+ isolates. By the same token, the clindamycin
resistance rate for the moxifloxacin-resistant A+B+ iso-
lates was 96.9% (63/65), but only 21.6% (8/37) for the
moxifloxacin-susceptible A+B+ isolates.
ErmB gene-specific PCR revealed that 17 of the 21 A-B+
isolates (81.0%) were ermB-positive. All 17 of these isolates
were resistant to clindamycin, and 16 (94.1%) showed high
level resistance (MIC> 256 mg/L). Among the 102 A+B+
isolates, there were 49 (48.0%) ermB-positive isolates, 37
of which (75.5%) were highly resistant to clindamycin.
Discussion
The prevalence of toxin A-negative/toxin B-positive (A-B+)
strains among CDI isolates varies depending on the coun-
try. In most of Europe and in North America, the preva-
lence of A-B+ strains has been reported to be only 0.2–8%
[6,24]; however, such strains are thought to have caused
several outbreaks in those regions. For example, in Poland
the prevalence of A-B+ strains has increased from 11% to
45% [25] since there was an outbreak. By contrast, Japan
has reported a high prevalence of A-B+ strains; the peak in-
cidence was 39% in 2000 [10], and the incidence decreased
to 12.7% in 2005–2008 [8]. A report from Shanghai
revealed that A-B+ strains were responsible for a third of
all CDI cases [4]. In Korea, the frequency of A-B+ strains
was reported to be 4.9% in 1998 [26], and it then increased
to 50.9% in 2004–2005 [7,11]. In our study, the frequency
of A-B+ strains among the HA-CDI patients in 2009 was
15.9%. Even given the expected fluctuations in time and
space, such a high frequency of A-B+ strains over the East
Asian region is interesting. Possible explanations could be
similar profiles of antibiotic use, and spread of the patho-
gen through common foods, as well as the heavy traffic of
people across the three countries.
The role of toxin A and toxin B in the pathogenecity
of CDI has been debated. Although early studies sug-
gested that toxigenic strains of C. difficile always produce
both toxin A and toxin B [5], one study showed that
toxin B is the key virulence factor [27]. However, a re-
cent study figured out that C. difficile producing either
one or both toxins showed cytotoxic activity in vitro that
translated directly into virulence in vivo [28]. Several stud-
ies of the clinical characteristics of A-B+ CDI [8,29-31] have
shown that A-B+ strains cause a wide spectrum of diseases
from asymptomatic colonization to life-threatening colitis
[31], and that there is no significant difference between
the clinical manifestations and outcomes of CDI caused by
Table 4 Multivariate analysis of risk factors for tcdA-
negative tcdB-positive (A-B+) Clostridium difficile
infections
OR 95% CI for Exp(B) p value
lower upper
Age 0.966 0.935 0.998 0.038
Sex 1.436 0.482 4.273 0.516
Albumin 2.584 0.901 7.412 0.077
COPD 2.269 0.462 11.153 0.313
Fluoroquinolone use 1.808 0.529 6.180 0.345
Clindamycin use 4.738 1.481 15.157 0.009
OR, odds ratio; CI, confidence interval; COPD, chronic obstructive pulmonary
disease.
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A-B+ and A+B+ strains [10]. However, another study
reported more cases of pseudomembranous colitis on en-
doscopy in A-B+ patients than in A+B+ patients (70% vs.
40%, p=0.0016) [11]. Furthermore, severe CDI caused
by PCR ribotype 017 was responsible for 5% of cases in
Germany, and all these cases had lethal outcomes [30]. In
another report, the mortality during a PCR ribotype 017
CDI outbreak attributable to that ribotype was similar to
that attributable to PCR ribotype 027 (7.0% vs. 6.5%), and
higher than that attributable to other types (7.0% vs. 1.6%)
[32]. Conversely, in our study there was no significant
difference in the clinical characteristics, the laboratory
findings or the incidence of pseudomembranous colitis be-
tween the study groups, and there were no deaths attribut-
able to A-B+ CDI. The clinical outcomes also did not differ
in the two groups, although there was no A-B+ CDI recur-
rence. In previous reports, the recurrence rate of A-B+ CDI
varied from 9 to 35.7% and was similar to that of A+B+
CDI [3,29]. The reason that we observed no recurrence
and no attributable death could be simply that the number
of A-B+ cases in this non-epidemic setting was too low. Al-
ternatively it could be because the A-B+ CDI developed in
younger patients with lower Charlson scores, or because
the shorter hospital stays among the A-B+ group prevented
re-infection (however that effect was not statistically sig-
nificant). Another possibility is that A-B+ CDI recurs less
frequently than A+B+ CDI. To investigate this, a further
study with a larger number of cases would be necessary.
In order to confirm that clindamycin use is an important
risk factor for A-B+ CDI in a clinical setting, we compared
the antimicrobial susceptibilities of the A-B+ and A+B+
strains. As expected [33], all 21 A-B+ strains were resistant
to clindamycin. High level resistance to clindamycin
(MIC> 256 mg/L) in C. difficile is usually linked to the
ermB gene, encoding resistance to macrolide-lincosamide-
streptogramin B (MLSB) [31]. In this study, the percentage
of ermB-positive strains was 53.7% among all C. difficile
isolates and 81.0% among the A-B+ isolates. Among the A-
B+ strains, 4 of the 21 isolates were ermB-negative, and all
of these were highly resistant to clindamycin. Clindamycin
resistance in these strains could also be induced by other
mechanisms such as other erm genes, efflux mechanisms,
or nucleotide substitutions in other genes [34]. Further
study of these resistance mechanisms would be desirable.
In previous studies, moxifloxacin resistance was closely
associated with clindamycin resistance (95% CI 68–97%)
[34,35]. It was reported that, of isolates resistant to fluoro-
quinolones, 98% were resistant to either erythromycin or
clindamycin, although fluoroquinolone resistance in the
absence of MLSB resistance was rare [35]. Similarly, in our
study, resistance to moxifloxacin was highly correlated
with clindamycin resistance (p< 0.0001). An efflux pump
may be responsible for the co-resistance to the MLSB
drugs and fluoroquinolone.
Conclusions
The prevalence of A-B+ strains among HA-CDI patients
in Korea was 15.9%. Disease severity and clinical charac-
teristics were not significantly different between the A-B+
and the A+B+ patients. Previous use of clindamycin is a
risk factor for acquisition of an A-B+ strain, and all tested
A-B+ isolates were highly resistant to clindamycin. Heavy
use of clindamycin appears to facilitate A-B+ strain infec-
tion in our hospitals.
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